Dibas; Mohammed I.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Dibas; Mohammed I..The latest application filed is for "pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases".

Company Profile

5.16.42

Dibas; Mohammed I. - Corona CA
Dibas; Mohammed I. - Laguna Niguel CA
Dibas; Mohammed I. - Mission Viejo CA US
DIBAS; MOHAMMED I. - LAGUAN NIGUEL CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Pharmaceutical Compositions Comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole Derivatives For Treating Retinal Diseases App 20220233505 - Dibas; Mohammed I. ; et al.	2022-07-28
Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases Grant 11,331,306 - Dibas , et al. May 17, 2	2022-05-17
Pharmaceutical Compositions Comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol App 20220008393 - Dibas; Mohammed I. ; et al.	2022-01-13
Pharmaceutical Compositions Comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole Derivatives For Treating Retinal Diseases App 20200390747 - Dibas; Mohammed I. ; et al.	2020-12-17
Pharmaceutical Compositions Comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol App 20200206193 - Dibas; Mohammed I. ; et al.	2020-07-02
Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases Grant 10,555,933 - Dibas , et al. Feb	2020-02-11
Pharmaceutical Compositions Comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole Derivatives For Treating Retinal Diseases App 20190240200 - Dibas; Mohammed I. ; et al.	2019-08-08
Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions Grant 10,201,535 - Dibas , et al. Feb	2019-02-12
Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect Grant 9,889,088 - Dibas , et al. February 13, 2	2018-02-13
Pharmaceutical Compositions Comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline For Treating Skin Diseases And Conditions App 20170182028 - Dibas; Mohammed I. ; et al.	2017-06-29
Pharmaceutical Compositions Comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol App 20170172983 - Dibas; Mohammed I. ; et al.	2017-06-22
Pharmaceutical Compositions Comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline For Treating Skin Diseases And Conditions App 20170095466 - Dibas; Mohammed I. ; et al.	2017-04-06
Ester Pro-drugs Of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] Methanol For Treating Skin Diseases And Conditions App 20160354346 - Dibas; Mohammed I. ; et al.	2016-12-08
Pharmaceutical Compositions Comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3himidazole Derivatives For Treating Retinal Diseases App 20160303083 - Dibas; Mohammed I. ; et al.	2016-10-20
Pharmaceutical Compositions Comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline For Treating Skin Diseases And Conditions App 20160151349 - Dibas; Mohammed I. ; et al.	2016-06-02
Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions Grant 9,308,201 - Dibas , et al. April 12, 2	2016-04-12
Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions Grant 9,283,217 - Dibas , et al. March 15, 2	2016-03-15
Pharmaceutical Compositions Comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol App 20160067222 - Dibas; Mohammed I. ; et al.	2016-03-10
Pharmaceutical Compositions Comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8- Tetrahydro-quinoline For Treating Skin Diseases And Conditions App 20160051534 - Dibas; Mohammed I. ; et al.	2016-02-25
N-(imidazolidin-2-ylidene)quinoline Derivatives As Modulators Of Alpha 2 Adrenergic Receptors App 20160045489 - Sinha; Santosh C. ; et al.	2016-02-18
N--(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors Grant 9,199,989 - Wang , et al. December 1, 2	2015-12-01
Pharmaceutical Compositions Comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3himidazole Derivatives For Treating Retinal Diseases App 20150250764 - Dibas; Mohammed I. ; et al.	2015-09-10
Pharmaceutical Compositions Comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline For Treating Skin Diseases And Conditions App 20150231128 - Dibas; Mohammed I. ; et al.	2015-08-20
Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases Grant 9,095,576 - Dibas , et al. August 4, 2	2015-08-04
Ester Pro-drugs Of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] Methanol For Treating Skin Diseases And Conditions App 20150148394 - Dibas; Mohammed I. ; et al.	2015-05-28
N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors Grant 9,034,896 - Sinha , et al. May 19, 2	2015-05-19
N-(imidazolidin-2-ylidene)quinoline Derivatives As Modulators Of Alpha 2 Adrenergic Receptors App 20140329852 - Wang; Liming ; et al.	2014-11-06
Ester pro-drugs of [3-(1-(1H-imidazol-4-YL)ethyl)-2-methylphenyl] methanol for treating retinal diseases Grant 8,853,251 - Dibas , et al. October 7, 2	2014-10-07
Alpha-2 Adrenergic Agonist For Treating Intraocular Pressure And Ocular Diseases Through Intravitreal And Intracameral Routes App 20140275197 - DIBAS; Mohammed I. ; et al.	2014-09-18
N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors Grant 8,815,861 - Sinha , et al. August 26, 2	2014-08-26
N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS App 20140228395 - SINHA; SANTOSH C. ; et al.	2014-08-14
N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors Grant 8,741,921 - Sinha , et al. June 3, 2	2014-06-03
Ester Pro-drugs Of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] Methanol For Treating Retinal Diseases App 20140057958 - DIBAS; Mohammed I. ; et al.	2014-02-27
N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS App 20130324571 - Sinha; Santosh C. ; et al.	2013-12-05
Ester Pro-drugs Of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] Methanol For Treating Skin Diseases And Conditions App 20130296394 - Dibas; Mohammed I. ; et al.	2013-11-07
Ester Pro-drugs Of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] Methanol For Lowering Intraocular Pressure App 20130289088 - Dibas; Mohammed I. ; et al.	2013-10-31
N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors Grant 8,513,419 - Sinha , et al. August 20, 2	2013-08-20
Alpha-2 Adrenergic Agonist Having Long Duration Of Intraocular Pressure-lowering Effect App 20130210876 - DONELLO; JOHN E. ; et al.	2013-08-15
Pharmaceutical Compositions Comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline For Treating Skin Diseases And Conditions App 20130203809 - Dibas; Mohammed I. ; et al.	2013-08-08
Pharmaceutical Compositions Comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline For Retinal Neuroprotection App 20130137724 - Dibas; Mohammed I. ; et al.	2013-05-30
Pharmaceutical Compositions Comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole Derivatives For Treating Retinal Diseases App 20130131133 - Dibas; Mohammed I. ; et al.	2013-05-23
Pharmaceutical Compositions Comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline For Treating Skin Diseases And Conditions App 20130123303 - Dibas; Mohammed I. ; et al.	2013-05-16
Pharmaceutical Compositions Comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine For Treating Retinal Diseases App 20130046003 - Dibas; Mohammed I. ; et al.	2013-02-21
N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS App 20130030014 - Sinha; Santosh C. ; et al.	2013-01-31
N-(imidazolidin-2-ylidene)quinoline Derivatives As Modulators Of Alpha 2 Adrenergic Receptors App 20130029994 - Sinha; Santosh C. ; et al.	2013-01-31
Pharmaceutical Compositions Comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine For Treating Skin Diseases App 20130023572 - Dibas; Mohammed I. ; et al.	2013-01-24
Ester Pro-drugs Of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] Methanol For Treating Retinal Diseases App 20120149746 - Dibas; Mohammed I. ; et al.	2012-06-14
Ester Pro-drugs Of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] Methanol For Lowering Intraocular Pressure App 20120142746 - Dibas; Mohammed I. ; et al.	2012-06-07
Ester Pro-drugs Of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] Methanol For Treating Skin Diseases And Conditions App 20120136036 - Dibas; Mohammed I. ; et al.	2012-05-31
S1P3 Receptor Inhibitors for Treating Conditions of the Eye App 20120071448 - Donello; John E. ; et al.	2012-03-22
S1p3 Receptor Inhibitors For Treating Inflammation App 20110009453 - Donello; John E. ; et al.	2011-01-13

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.